Randomized R2-CHOP studies in DLBCL

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Grzegorz Nowakowski from Mayo Clinic, Rochester, US, about the randomized R2-CHOP studies in DLBCL presented. Grzegorz Nowakowski spoke about the two studies that combined lenalidomide with R2-CHOP, the ROBUST study, a large phase III study, and the ECOG 1412 study, a smaller, randomized phase II study.